1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysisA. Clamp, JA Ledermann, Axel Walther et al.|Annals of Oncology|2025Cited by 3